Browsing by Author "Economopoulos, T."

Now showing items 21-26 of 26

    • Article  

      Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study 

      Psyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, Anna; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, Gerasimos; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, Dimitrios; Pavlidis, Nicholas; Economopoulos, T.; Fountzilas, George (2012)
      Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the ...
    • Article  

      Prognostic variables in Greek patients with stage II breast cancer: A Hellenic Cooperative Oncology Group Study 

      Fountzilas, George; Vasilaros, S.; Koukouras, D.; Malamos, N.; Pectasides, Dimitrios; Adamou, A.; Nenopoulou, E.; Kiriakou, K.; Zouvani, I.; Katsohis, C.; Kappas, A. M.; Skopa, C.; Semoglou, C.; Fahantidis, E.; Konstantaras, C.; Vasilaki, E.; Economopoulos, T.; Bacoyiannis, Charalambos; Bafaloukos, Dimitrios; Razi, E. D.; Polichrnis, A.; Androulakis, G.; Papaioannou, T.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A. (1997)
      The independent effects of several patient, tumor and treatment-related prognostic factors on relapse-free survival (RFS) and overall survival (OS) were assessed by Cox multivariate regression analysis in 988 Greek patients ...
    • Article  

      Rituximab in combination with CNOP chemotherapy in patients withn previously untreated indolent non-Hodgkin's lymphoma 

      Economopoulos, T.; Fountzilas, George; Pavlidis, Nicholas; Kalantzis, Dimitrios; Papageorgiou, E.; Christodoulou, C.; Hamilos, G.; Nikolaides, C.; Dimopoulos, M. A. (2003)
      Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy. The purpose ...
    • Article  

      Second malignancies following treatment for Hodgkin's disease: A Greek experience 

      Economopoulos, T.; Stathakis, N.; Alexopoulos, C.; Pavlidis, Nicholas; Constantinidou, M.; Briassoulis, E. Ch; Papageorgiou, E.; Dervenoulas, John; Pappa, Vassiliki; Vaslamatzis, M.; Raptis, S. (1994)
      The risk and the type of second malignancies (SM) developing in 217 treated Hodgkin's disease (HD) patients were studied. The median age of the patients was 35 years (range 14-83) and the M/F ratio 1.8. Treatment consisted ...
    • Article  

      Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival 

      Kostadima, Lida; Pentheroudakis, George; Fountzilas, George; Dimopoulos, M. A.; Pectasides, Dimitrios; Gogas, H.; Christodoulou, C.; Samantas, E.; Bafaloukos, Dimitrios; Arapantoni, P.; Kalofonos, H. P.; Papakostas, P.; Economopoulos, T.; Bamias, A. T.; Pavlidis, Nicholas; Stropp, U.; Wirtz, R. M.; Hennig, G. (2006)
      Introduction: Glycodelin and survivin are key polypeptide regulators of cellular proliferation, apoptosis and angiogenesis. In view of contradictory reports on their functional role in tumors, we studied their transcriptional ...
    • Article  

      Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP 

      Economopoulos, T.; Dimopoulos, M. A.; Mellou, S.; Pavlidis, Nicholas; Samantas, E.; Nikolaides, C.; Tsatalas, C.; Papadopoulos, A.; Papageorgiou, E.; Papasavvas, P.; Fountzilas, George (2002)
      Introduction: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has ...